Professional Documents
Culture Documents
Psychiatric or Psychopharmacological Effects of Hormones: Andrea Marquez Lopez Mato
Psychiatric or Psychopharmacological Effects of Hormones: Andrea Marquez Lopez Mato
PSYCHOPHARMACOLOGICAL
EFFECTS OF HORMONES
JUST REMEMBER
T4 is the predominant hormone released
with the majority of T3 being formed in the
periphery by enzymatic deiodination.
RATIONALE
• Treatment-resistant depressed women, may have a
high frequency of serum thyroxine levels near the
lower limit of normal; who only respond after T3 was
added to their antidepressant regime
• Low dose (5-50 mg/d) T3 "augmentation therapy" is
the best documented treatment with thyroid hormones
in depression
Ia- Unipolar Treatment Refractory
depressives receiving thyroid
hormone as add-on therapy
RATIONALE (cont)
80
70
60
50
40
30
20
10
response remission
0
Ib- Treatment refractory “rapid cycling”
bipolar depressive patients on add-on
therapy with T4
RATIONALE
• High-dose (250-500 micrograms/d) T4 is a well
documented therapy for "rapid cycling bipolar
disorder” refractory to lithium
Ib- Treatment refractory “rapid cycling”
bipolar depressive patients on add-on
therapy with T4
90% responded
Measured by
• Clinical evaluation
• Subjective impression
• Beck inventory or HAMD
Improved remission rates
Cycle switch was less evident
Ib- Treatment refractory “rapid cycling”
bipolar depressive patients on add-on
therapy with T4
90
80
70
60
50
40
30
20
10
0 response less switching
in 5 years
II- Females with menopausal
depression receiving estrogen,
progestin, tibolone, soy bean
• IIa - Females with menopausal depression receiving
soy bean natural supplements
ns
s
ns
in
tin
e
EA Ms
ge
og
st
S
s
R
r
e
ge
ST ER
ro
t
og
nd
o
S
E
Pr
Pr
A
/
s/
ns
n
ge
ge
o
ro
tr
t
Es
Es
IIa- 50 patients receiving ATD therapy with
or without soybean preparations
90
Percentage of improved
80
70
60
patients
50 ATD plus
40
Soy bean
30 derivates
20
10 ATD alone
0
90
Improvement 85
80%
80
ATD
75 plus
tibolone ATD alone
70
70
Improvement in depression
60
RTH with
56%PG
Natural
50
40
30 RTH32%
with
RHT with
any
20 Medroxi-
progestins
PG
10
RATIONALE
• DHEA is a precursor hormone which counteracts
the aging and immuno-suppressive effects
caused by corticosteroids
RATIONALE (cont)
• Several studies adress the benefits of a long-
term (1 year), medium dose of 50- 100 mgs/d
replacement therapy in different groups of aging
men who presented clinical characteristics of
partial androgen deficiency (PADAM)
III- PADAM patients receiving DHEA
supplements
• 44 patients
• HAM D ≥ 15
• Receiving several ATD therapies
• 21 received ATD alone
• 23 received DHEA suplementation
III PADAM patients receiving DHEA
supplements
76%
80
70
Clinical 60 48%
Improvement
50
DHEA
40
30
20
10 No DHEA
0
IV - CFS patients receiving DHEA
RATIONALE
• Chronic Fatigue Syndrome (CFS) is
characterized by a persistent debilitating
fatigue, muscle & joint related symptoms and
neuropsychiatric symptoms
• Pathogenesis is associated with abnormalities
of the endocrine system with impairment of the
adrenal axis response
IV- CFS patients receiving DHEA
RATIONALE
• Majority of patients with CFS have a serum
cortisol and dehydroepiandrosterone sulfate
(DHEA-S) deficiency which might be related to
the neuropsychiatric symptoms
IV- CFS patients receiving DHEA as
add-on therapy
80 Duloxetine
78
76
74 Duloxetine
plus
72
pregabalin
70
68 Duloxetine
Plus
66 pregabalin
64 plus DHEA
PSYCHOPHARMACOLOGICAL
EFFECTS OF HORMONES
CONCLUSIONS